Oragenics (OGEN) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Oragenics
Is Oragenics a buy right now? The alternative data says hold. This OGEN stock analysis is built on the 25+ alternative data signals AltIndex tracks on Oragenics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 52/100: a Hold. The stock trades at $0.49 with a $2M market cap.
The data leans positive over the past 90 days — web traffic up 80.1% to 5K monthly visits — but the move hasn’t been broad enough to lift OGEN into buy territory yet.
OGEN’s broader alt-data profile also covers headcount (18 employees, according to LinkedIn), and sentiment (7/100). Every signal links to its own page with full history, the OGEN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on OGEN is just below.
Oragenics AI Stock Analysis
Oragenics, Inc. is a biopharmaceutical company engaged in the research and development of innovative therapies for oral health and infectious diseases. The company's primary focus lies in producing novel antibiotics against infectious diseases and developing effective treatments for oral mucositis.
Analysis generated October 2, 2026.
Recent Oragenics Stock Alerts
|
Oragenics | September 23 Price is down by -6.7% in the last 24h. |
|
Oragenics | September 21 Price is up by 8% in the last 24h. |
|
Oragenics | September 2 Price is up by 6.8% in the last 24h. |
|
Oragenics | August 31 Price is down by -6.5% in the last 24h. |
Oragenics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 80.1% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 18 | 0% | |
| Sentiment | 7 | N/A | |
| Reddit Mentions | 0 | 100.0% | |
| X Mentions | 1 | 80.0% | |
| Stocktwits Mentions | 21 | 16.7% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 42K | 0% | |
| 4chan Mentions | 0 | N/A |
About Oragenics (OGEN)
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
| Price | $0.49 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $2M |
| Year Range | $0 – $1 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Oragenics News
View more →
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21May 19 - GlobeNewswire |
|
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic InflammationMay 7 - GlobeNewswire |
|
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.May 5 - GlobeNewswire |
|
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryApril 13 - GlobeNewswire |
|
Oragenics, Inc. Receives Audit Opinion with Going Concern ExplanationMarch 25 - GlobeNewswire |
See Oragenics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for OGEN, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEOragenics Earnings & Financial Performance
View all earnings →Oragenics Insider Trading Activity
View all →| Telling Fred filed to sell 34,538 shares at $0.0. Dec 12 '25 |
| Telling Fred filed to sell 948 shares at $0.0. Dec 12 '25 |
| Odyssey Health, Inc. filed to sell 0 shares at $0.0. Jun 18 '25 |
| Odyssey Health, Inc. filed to sell 5,044 shares at $0.0. Jun 17 '25 |
| Odyssey Health, Inc. filed to sell 7,044 shares at $0.0. Jun 16 '25 |
Oragenics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Oragenics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
GenprexGNPX |
$2.61 4.0% | $2M | 46 |
 |
Clearside BiomedicalCLSD |
$0.41 27.0% | $2M | 45 |
 |
Alaunos TherapeuticsTCRT |
$0.74 6.6% | $2M | 48 |
 |
BioXcel TherapeuticsBTAI |
$0.07 37.1% | $2M | 45 |
 |
Hepion PharmaceuticalsHEPA |
$0.12 20.0% | $2M | 57 |
Explore Oragenics Data
Frequently Asked Questions: Oragenics (OGEN)
Oragenics has an AltIndex AI Score of 52/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
52/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Oragenics (OGEN) stock is $0.49 with a market cap of $2M.
As of today, Oragenics’s PE (Price to Earnings) ratio is —.
View the latest Oragenics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Oragenics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The OGEN stock price chart above shows Oragenics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Oragenics technical analysis for RSI, moving averages, and more.
See the stocks similar to Oragenics section on this page for companies in the same industry ranked by market cap and AI Score.
